There are currently 651 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Children's Medical Center of Central Texas, Pfizer Investigational Site and DermResearch Inc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Texas Diabetes & Endocrinology, P.A., Austin, Texas +1 locations
Conditions: Obesity, Cardiovascular Diseases
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: US Dermatology Partners Jollyville, Austin, Texas
Conditions: Atopic Dermatitis
Register for Updates
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835
Recruiting
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
06/19/2024
Locations: Research Site, Austin, Texas
Conditions: Chronic Kidney Disease With High Proteinuria
Register for Updates
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06124807
Recruiting
The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: IMA Clinical Research Austin, Austin, Texas
Conditions: Obesity, Overweight and Obesity
Register for Updates
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
NCT06177912
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of age. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting invasive pneumococcal disease (IPD).
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/19/2024
Locations: Velocity Clinical Research, Austin ( Site 0129), Austin, Texas
Conditions: Pneumococcal Infection
Register for Updates
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
NCT05755906
Recruiting
This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/19/2024
Locations: Research Site, Austin, Texas
Conditions: Asthma
Register for Updates
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623
Recruiting
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Austin, Austin, Texas
Conditions: Urinary Bladder Neoplasms
Register for Updates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Austin Regional Clinic, Austin, Texas
Conditions: Arthritis, Psoriatic
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Ascension Texas Cardiovascular, Austin, Texas
Conditions: Atrial Fibrillation
Register for Updates
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
NCT06068868
Recruiting
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in esca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: St. David's South Austin Medical Center /ID# 252790, Austin, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820
Recruiting
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Austin, Austin, Texas
Conditions: Non-Muscle Invasive Bladder Cancer
Register for Updates
A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT05421663
Recruiting
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non-Hodgkin lymphoma (r/r B-NHL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: St. David's South Austin Medical Center, Austin, Texas
Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Register for Updates